Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04733040 | Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE) | PHASE2 | COMPLETED | 24 | — | — | Jan 20, 2021 | Dec 14, 2023 | Feb 7, 2025 | 25 | Georgia, Germany +5 |
efficacy of 2 different dosing regimens of MOR202 in subjects with anti-PLA2R antibody positive MN
| Arm | Type | Description |
|---|---|---|
| MOR202 5 Doses | EXPERIMENTAL | 5 doses administered on Day 1, 8, 15, 29, and 57 |
| MOR202 2 Doses | EXPERIMENTAL | 2 doses administered on Day 1 and 15 |
| Name | Type | Description |
|---|---|---|
| MOR202 | DRUG | MOR202 will be administered as an intravenous infusion |
Inclusion Criteria: * Subjects ≥ 18 to ≤ 80 years (at date of signing the informed consent form \[ICF\]). * Urine protein to creatinine ratio (UPCR) of ≥ 3.0 g/g or proteinuria ≥ 3.5 g/24 h * Estimated glomerular filtration rate (eGFR) ≥ 50 ml/min/1.73 m² (eGFR \>30 and \< 50 ml/min/1.73 m² can be ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Apellis Pharmaceuticals, Inc. | APLS | 2 | PHASE3 | Pegcetacoplan |